A need for predictive and personalized approach in osteoporosis treatment: individual treatment plan

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F22%3A10450044" target="_blank" >RIV/00216208:11140/22:10450044 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=PivkRg8EX-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=PivkRg8EX-</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

A need for predictive and personalized approach in osteoporosis treatment: individual treatment plan

Popis výsledku v původním jazyce

Osteoporosis is a frequent, multifactorial disease and represents a significant and increasing healthcare burden in Europe. For osteoporosis treatment several drugs groups (SERM: bisphosphonates, denosumab, teriparatide) have been approved with different biological effects and further are expected. The question if every medication is suitable for all patients, is opened. We may stratify patients by individual fracture risk assessment but often there many others individual factors affecting medication choice. Age, life expectancy, falls, kidney function are very important. Preparing individual treatment plans for each patient is the way how to handle with it. In younger osteoporotic women we have to expect 20-25 years of care and sequential therapy, long term therapy with &quot;drug holiday&quot; is to be considered. This new strategy should be accompanied by more flexible reimbursement rules.

Název v anglickém jazyce

A need for predictive and personalized approach in osteoporosis treatment: individual treatment plan

Popis výsledku anglicky

Osteoporosis is a frequent, multifactorial disease and represents a significant and increasing healthcare burden in Europe. For osteoporosis treatment several drugs groups (SERM: bisphosphonates, denosumab, teriparatide) have been approved with different biological effects and further are expected. The question if every medication is suitable for all patients, is opened. We may stratify patients by individual fracture risk assessment but often there many others individual factors affecting medication choice. Age, life expectancy, falls, kidney function are very important. Preparing individual treatment plans for each patient is the way how to handle with it. In younger osteoporotic women we have to expect 20-25 years of care and sequential therapy, long term therapy with &quot;drug holiday&quot; is to be considered. This new strategy should be accompanied by more flexible reimbursement rules.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Osteology

ISSN

2571-1326

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

4

Strana od-do

13-16

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85134150760